@article{e7af445004c9493dbc11dbe33e94921d,
title = "Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?",
author = "Satish Shanbhag and Vinay Prasad",
note = "Funding Information: Dr. Prasad reports receiving royalties from his book Ending Medical Reversal, that his work is funded by the Laura and John Arnold Foundation, that he has received honoraria for Grand Rounds/lectures from several universities, medical centers, nonprofit groups, professional societies, and is a writer for Medscape. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",
year = "2018",
month = nov,
doi = "10.1016/j.ejca.2018.09.021",
language = "English (US)",
volume = "104",
pages = "252--253",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
}